<i>N</i>-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers
作者:Michael Grasso、Michelle A. Estrada、Kiara N. Berrios、Jeffrey D. Winkler、Ronen Marmorstein
DOI:10.1021/acs.jmedchem.8b00499
日期:2018.6.14
stabilize an inactive αC-out/αC-out homodimeric conformation with improved inhibitor potency and selectivity in vitro. We set out to extend this strategy to target RAF homo- and heterodimers with the pan-RAF inhibitor TAK632 in dimeric configuration. Surprisingly, we find that monomeric TAK632 induces an active αC-in/αC-in BRAF dimer conformation, while dimeric TAK inhibitors cannot promote BRAF dimers
BRAF V600E是黑色素瘤中最常见的激活突变,接受BRAF V600E抑制剂治疗的患者均在一年内产生耐药性。一个重要的抗性途径是涉及BRAF二聚体的反常激活(反式激活),由此抑制剂结合的蛋白亚基变构地激活其他亚基。我们最近报道了BRAF V600E二聚体选择性维罗非尼抑制剂,可稳定无活性的αC-out/αC-out同型二聚体构象,并在体外具有增强的抑制剂效价和选择性。我们着手将这一策略扩展为以二聚体构型的pan-RAF抑制剂TAK632靶向RAF同型和异二聚体。出乎意料的是,我们发现单体TAK632诱导了活跃的αC-in/αC-inBRAF二聚体构象,而二聚体TAK抑制剂则不能促进BRAF二聚体,并且在体外具有显着降低的效能。这些研究揭示了BRAF二聚化与TAK632抑制模式之间的密切联系,并强调了理解BRAF抑制剂对激酶二聚化影响的重要性。